ALEC News

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

Alector (NASDAQ:ALEC) is putting $75 million on the table in a major financing move that could help fuel its next chapter in the race to develop treatments for Alzheimer’s, Parkinson’s and other devastating neurological disorders. The South San Francisco biotech priced an underwritten offering of 36.6 million common shares at $2.05 apiece, approximately 7.3% above its October 15 closing price.

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.

Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...

Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...

This week’s action puts Alector (NASDAQ:ALEC), NeOnc Technologies (NASDAQ:NTHI), WISeQey (NASDAQ:WKEY), Veea (NASDAQ:VEEA), and Stablecoin Development Corporation (NYSEAMERICAN:SDEV) squarely in that conversation.

Alector (NASDAQ:ALEC) just transformed one of its most important neuroscience programs into a potentially billion-dollar commercial opportunity.

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...